Citi is out with its report today on Hologic HOLX, maintaining Buy.
In a note to clients, Citi writes, "Hologic recently presented at our annual healthcare conference in NYC and reviewed its strategic plan and gave further detail on initial customer interest for tomosynthesis – recall the product was approved on 2/11/11. The company also fielded investor questions on its outstanding convertible debt and the Cervista HPV opportunity. We maintain our Buy rating and $24 target price. The main focus for the stock remains the tomosynthesis launch."
Shares of HOLX closed Friday at $21.08, down 0.28% from Thursday's close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.